Literature DB >> 29165417

[Pterygium: etiology, pathogenesis, treatment].

S A Malozhen1, S V Trufanov1, D A Krakhmaleva1.   

Abstract

Pterygium is a degenerative condition characterized by fibrovascular outgrowth of conjunctiva over the cornea. Many theories exist that try to explain its pathogenesis. The current belief is that this disease is multifactorial with ultraviolet radiation being the most important trigger. Attention is also paid to such factors as tear film changes, cytokines and growth factors disbalance, immunologic disturbances, genetic mutations, and viral infections. Modern classifications consider the rate of fibrovascular growth, its progressive potential, and histological features. In the beginning pterygium is usually asymptomatic, however, dry eye manifestations may be present, such as burning, itching, and/or tearing. As the lesion grows toward the optical zone, visual acuity gets compromised, and thus, surgical treatment is required. Because of recurrences and repeated surgeries, the growth of the lesion may become more aggressive and cause irregular astigmatism. Comprehensive surgery of pterygium is aimed at not only removing the lesion, but also preventing recurrences. Advisable are modified bare sclera techniques with subsequent transposition of the conjunctival flap, conjunctival autotransplantation, amniotic membrane transplantation, and peripheral lamellar keratoplasty (in cases of significant ingrowth). In some cases, antirecurrent adjuvant therapy may be considered that involves the use of mitomycin C, 5-fluoruracil, and VEGF inhibitors. However, the search for the best treatment for pterygium, i.e. an easy to perform, cosmetically-friendly method associated with minimal risk of recurrences and/or complications, remains an interest of modern ophthalmology.

Entities:  

Keywords:  5-fluoruracil; amniotic membrane transplantation; anti-VEGF; bevacizumab; conjunctival autotransplantation; doxycycline; etiology; mitomycin C; pathogenesis; peripheral lamellar keratoplasty; pterygium; recurrence prevention

Mesh:

Year:  2017        PMID: 29165417     DOI: 10.17116/oftalma2017133576-83

Source DB:  PubMed          Journal:  Vestn Oftalmol        ISSN: 0042-465X


  7 in total

Review 1.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Elevation of S100 calcium-binding protein A7 in recurrent pterygium.

Authors:  Yuru Zhang; Fei Liu
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

3.  Dynamic thiol disulphide homeostasis in patients with surfer's eye: a case-control study.

Authors:  Hanife Tuba Akcam; Ozcan Erel
Journal:  Int Ophthalmol       Date:  2021-11-23       Impact factor: 2.031

4.  Protective Role of Glutathione and Nitric Oxide Production in the Pathogenesis of Pterygium.

Authors:  Fidelina Parra; Alexander Kormanovski; Gustavo Guevara-Balcazar; María Del Carmen Castillo-Hernández; Antonio Franco-Vadillo; Mireille Toledo-Blas; Rosa Adriana Jarillo-Luna; Eleazar Lara-Padilla
Journal:  J Ophthalmol       Date:  2020-08-29       Impact factor: 1.909

5.  Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium.

Authors:  Siying He; Hui Sun; Yifang Huang; Shiqi Dong; Chen Qiao; Shuai Zhang; Chen Wang; Fang Zheng; Ming Yan; Guohua Yang
Journal:  Biomed Res Int       Date:  2019-06-25       Impact factor: 3.411

6.  Immunohistochemical study of STAT3, HIF-1α and VEGF in pterygium and normal conjunctiva: Experimental research and literature review.

Authors:  Shiqi Dong; Xiying Wu; Yuting Xu; Guohua Yang; Ming Yan
Journal:  Mol Vis       Date:  2020-07-26       Impact factor: 2.367

7.  Effect of Pterygium Removal Combined with Conjunctival Autograft on Corneal Parameters in Swept-Source Imaging.

Authors:  Marta P Wiącek; Monika Kuśmierz-Wojtasik; Bogna Kowalska; Anna Machalińska
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.